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Patients with hemophagocytic lymphohistiocytosis (HLH) exhibit immune hyper-activation
as a consequence of genetic defects in secretory granule proteins of cytotoxic T lympho-
cytes (CTL) and natural killer (NK) cells. Murine models of HLH demonstrate significant
activation of CTL as central to the disease pathogenesis, but evaluation of CTL and NK
activation in children with HLH or inflammatory conditions is not well described. CD8 T
cells only express granzyme B (GrB) following stimulation and differentiation into CTL;
therefore, we reasoned that GrB expression may serve as a signature of CTL activation. It
is unknown whether human NK cells are similarly activated in vivo, as marked by increased
granule proteins. Perforin and GrB levels are measured in both CTL and NK cells by flow
cytometry to diagnose perforin deficiency. We retrospectively compared GrB expression
in blood samples from 130 children with clinically suspected and/or genetically defined
HLH to age-matched controls. As predicted, CD8 expressing GrB cells were increased in
HLH, regardless of genetic etiology. Remarkably, the GrB protein content also increased
in NK cells in patients with HLH and decreased following immunosuppressive therapy.
This suggests that in vivo activation of NK cells occurs in hyper-inflammatory conditions.
We conclude that increased detection of GrB in CTL and NK are an immune signature for
lymphocyte activation in HLH, irrespective of genetic subtype and may also be a useful
measure of immune activation in other related conditions.
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INTRODUCTION
Cytotoxic lymphocytes utilize the perforin/granzyme pathway for
target-cell killing in both the innate and adaptive immune response
(Russell and Ley, 2002; Voskoboinik et al., 2006; Lieberman, 2010).
Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells con-
tain specialized secretory lysosomes, cytotoxic granules, which
degranulate upon contact with a target-cell. These granules con-
tain perforin (Prf), a membrane-disrupting protein that facilitates
the delivery of granzymes, granule proteases that initiate apoptotic
death in target-cells.
In humans, genetic defects in the pathway for Prf-mediated
lymphocyte cytotoxicity is associated with a primary immun-
odeficiency presenting with profound systemic inflammation
in infancy, familial hemophagocytic lymphohistiocytosis (HLH)
(Filipovich, 2009; Risma and Jordan, 2012). Mutations in seven
genes have been associated with familial HLH phenotypes (PRF1,
UNC13D, STX11, RAB27A, STXBP2, SH2D1A, and BIRC4). Five
Abbreviations: CMV, cytomegalovirus; CTL, cytotoxic T lymphocytes; EBV, Epstein
Barr virus; GrB, granzyme B protein; HLH, hemophagocytic lymphohistiocytosis;
MCF, mean channel fluorescence; NK, natural killer; Prf, perforin protein; sIL2R,
soluble IL-2 receptor alpha (sCD25).
of these genes express proteins (Prf, Munc 13-4, Rab 27a, Syntaxin
binding protein 2, and Syntaxin 11) involved in the function of
cytotoxic secretory granules, and biallelic genetic mutations lead
to impaired Prf-dependent cytotoxicity by impairing Prf function
or degranulation of cytotoxic granules (de Saint Basile et al., 2011).
The latter two genes (SH2D1A and BIRC4) encode slam associated
protein (SAP) and X-linked inhibitor of apoptosis protein (XIAP)
and defects are identified in boys with X-linked lymphoprolifera-
tive disease (XLP types 1 and 2), a primary immunodeficiency that
may present with HLH, especially upon infection with Epstein
Barr Virus (EBV) (Marsh and Filipovich, 2011). SAP deficiency
impairs NK and CTL mediated killing of EBV-infected B cells
(Cannons et al., 2011). Although clearly associated with HLH
(Marsh et al., 2010; Pachlopnik Schmid et al., 2011), the impact of
XIAP deficiency on Prf-mediated lymphocyte cytotoxicity remains
unclear.
The clinical symptoms of HLH (irrespective of geno-
type) include fever, lymphadenopathy, jaundice, and men-
tal status changes, and the pathologic signs include pan-
cytopenia, hypercytokinemia, and multisystem organ failure.
Hemophagocytosis is frequently seen on bone marrow or liver
biopsy, but is variably present on a single biopsy. An immune
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trigger, such as a viral infection, may or may not be identified.
Genetically defined, or primary, HLH is generally fatal unless
treated with immune suppression and ultimately bone marrow
transplant (Jordan and Filipovich, 2008; Trottestam et al., 2011).
The pathophysiology of HLH has been modeled in Prf1-
deficient and Unc13d deficient mice (Jordan et al., 2004; Crozat
et al., 2007). Severe immune dysregulation occurs in response to
lymphocytic choriomeningitis virus (LCMV) infection of these
genetically defined mice. Jordan and colleagues have shown that
the development of HLH phenotype in Prf1-deficient mice is
dependent upon and defined by dramatic hyper-activation of CTL
(Lykens et al., 2011), suggesting that CTL activation may be a
reproducible immune signature for HLH. It is unknown whether
human CTL and NK are similarly hyper-activated during the clin-
ical course of HLH. Indeed, studies of immune activation in HLH
and other systemic inflammatory disorders have focused primarily
on non-specific markers of lymphocyte and monocyte activation
such as soluble IL-2 receptor alpha (sIL2R or sCD25) and soluble
CD163 (Komp et al., 1989; Imashuku et al., 1995; Bleesing et al.,
2007; Johnson et al., 2011). Elevated sIL2R levels are utilized as a
gold standard, measure of immune activation for HLH, but may be
elevated in other lymphoproliferative disorders as well (Bien and
Balcerska, 2008). Therefore, we considered whether detection of
granule proteins induced in cytotoxic lymphocytes central to the
pathogenesis of HLH may herald the immune hyper-activation
that is characteristic of HLH.
Granzyme B (GrB) protein levels in human CTL and NK
increase following activation in vitro (Salcedo et al., 1993; Gross-
man et al., 2004; Sedelies et al., 2004; Buzza and Bird, 2006; Skak
et al., 2008; Kim et al., 2011; Wang et al., 2012). Recent stud-
ies have focused on the utility of soluble GrB in the blood as a
biomarker of immune activation in humans with a variety of dis-
orders, including autoimmune disease, graft rejection, and viral
infection (Spaeny-Dekking et al., 1998; Tak et al., 1999; Goldbach-
Mansky et al.,2005; Buzza and Bird,2006;Altimari et al.,2008; Bem
et al., 2008; Truong et al., 2008; Boivin et al., 2009). It is assumed
that the elevated blood granzyme levels are due to increased GrB
expression by CTL activation; however the contribution from NK
cells is unknown. We hypothesized that GrB protein levels in both
CD8 T cells (activated CTL) and NK cells would increase sec-
ondary to immune activation in patients with HLH. Compared
to age-matched controls, we observed that GrB protein expression
was increased in both CTL and NK cells of patients with HLH,
irrespective of genetic etiology. GrB levels in NK cells also corre-
lated with disease activity. Therefore, human NK cells, like CTL,
acquire enhanced GrB protein expression in pro-inflammatory
conditions, suggesting a mechanism for up-regulation of cytotoxic
function.
MATERIALS AND METHODS
PATIENTS
With approval from the institutional review board (IRB), we retro-
spectively reviewed clinical data listed on Diagnostic Immunology
Laboratory (DIL) test requisition forms, immune testing results,
and genetic testing results from patients referred for testing to
our center between 2001 and 2011. We defined sub-groups of
patients with genetically defined HLH accordingly (see Table 1):
Table 1 | Group cohort with HLH.
Clinical/genetic
subtype
Number of patients
(n) total 130
Age at
diagnosis
FHL2 (PRF1) 53 1 wk–22 yr
FHL3 (UNC13D) 20 3 wk–10 yr
FHL5 (STXBP2) 10 12 mo–16 yr
HLHxlp (SH2D1A or BIRC4) 10 6 wk–17 yr
HLHunk 23 2 wk–16 yr
HLHEBV 14 3 mo–17 yr
Wk, week; mo, month; yr, year.
(1) FHL2- biallelic PRF1 mutations, (2) FHL3- biallelic UNC13D
mutations, (3) FHL5-biallelic STXPB2 mutations, and (4) HLHxlp
associated with XLP (mutations in SH2D1A or BIRC4). Data from
five patients with XLP but no evidence of HLH were also compared
to boys with HLHxlp.
For comparison, we evaluated a group of patients whose genetic
diagnoses were not established HLHunk, by reviewing data from
over 800 patient blood samples (ages 0–22 years) submitted to this
institution’s DIL between 06/2001 and 07/2007 for Prf detection
by flow cytometry as part of an evaluation for suspected HLH. Our
goal was to utilize stringent criteria for inclusion of patients so as
to eliminate samples where the diagnosis of HLH was not con-
firmed. Therefore, in the HLHunk group we included only patients
with a diagnosis of HLH documented by the ordering physician
on the sample requisition (or documented following evaluation at
our hospital) and an elevated sIL2R. The requirement for elevated
sIL2R was not utilized as a criterion for inclusion of patients with
documented gene mutations to include the maximum number of
children with genetically defined HLH. For the majority of cases, it
was not known if a patient had already begun treatment at the time
of sample submission. A subset of patients with a clinical history
of HLH due to EBV infection documented on the test requisi-
tion (HLHEBV) and unknown genotype was considered separately
(n= 14).
In a follow-up analysis, 10 children with HLH were evaluated
following and/or during clinical treatment for HLH at this institu-
tion. These patients were included if they had repeat testing with
both sIL2R and Prf/GrB staining on the same day at a discrete
time following treatment. A description of their clinical features is
included in Table 2.
CONTROL GROUP
Samples from healthy children (age 0–20) and adults (>20 years)
were obtained and analyzed for GrB expression in NK cells and
cytotoxic lymphocytes to establish normal ranges in our labo-
ratory as we previously described for Prf (Kogawa et al., 2002).
Residual peripheral blood samples obtained in ethylenediaminete-
traacetic acid for complete blood counts (CBC) were retrieved
from an outpatient clinic at our institution under an agreement
approved by the IRB. The samples included the age and gender of
the patient and the result of the CBC. Those samples with CBC or
differential parameters outside of the normal range for age were
excluded from the study and discarded. All samples were held at
room temperature and processed within 24 h of collection.
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Table 2 | Granzyme B detection in NK and CTL before and after
treatment for HLH, prior to BMT.
HLH etiology Age of
onset HLH
SIl2r
(pg/ml)
% GrB
+ CD8
GrB MCF in
NK (783±83)
P1 HLHEBV 8yr 137,269 50 2822
45,231 14 2862
P2 HLHxlp (BIRC4) 6 wk 25,496 96 2509
9,410 8 1681
P3 HLHxlp (BIRC4) 4 mo 20,748 39 3198
2,078 4 1231
P4 FHL5 12yr 51,646 36 2312
883 15 833
P5 FHLunk 7 yr 5,323 74 2599
1,050 30 970
P6 HLHEBV 8 yr 12,280 44 2173
900 4 960
P7 FHL5 2 yr 8,566 49 1670
1,002 11 1137
P8 FHL2 5 yr 15,647 69 1812
1,701 98 986
P9 FHL5 4 yr 29,400 81 2048
656 3 1219
P10 HLHxlp (BIRC4) 16 mo 15888 64 2094
1876 50 1061
For each patient, serial lab evaluations are displayed by row. Labs that are elevated
compared to control values are shaded. The normal control values for sIL2R and
GrB in CD8 are age and assay dependent-therefore healthy control values are not
listed (See Figure 1 for GrB). The control values for GrB in NK is based on 97
children, aged 0–20 years and represents the 99% confidence interval (parenthe-
ses). As >95% of NK cells in patients are GrB (+), only the variable value of MCF
is shown.
FLOW CYTOMETRIC ANALYSIS (PERFORIN/GRANZYME B STAINING)
Perforin and GrB staining was performed by using standard pro-
cedures as described in previous publications (Kogawa et al., 2002;
Molleran Lee et al., 2004). The antibodies used were either PE-
conjugated anti-Prf (deltaG9, BD Pharmingen) or PE-conjugated
anti-GrB (GB12, Caltag Laboratories, Burlingame, CA, USA).
Detection of Prf and GrB expression by flow cytometry in patients
and healthy controls was performed using anti-TCRαβ FITC,
anti-CD8PerCP, and anti-CD56 APC antibodies (BD) for surface
staining and isotype controls for intracellular staining. CD56+
T cells were excluded from the analysis of NK cells. Samples were
analyzed using a FACSCalibur or FACSCanto flow cytometer (Bec-
ton Dickinson, San Jose, CA, USA). The normal range for the
percentage and mean channel fluorescence (MCF) of Prf and GrB
in NK cells is age-independent (see Results) and was constant for
all daily controls from 2001 to 2009 using FACSCalibur machines.
Daily standardization takes place on the flow cytometers using
commercial beads with established amounts of fluorescence. With
use of the FACSCanto introduced in 2009, a new normal range for
the MCF of Prf and GrB was established. Therefore, in the group
analysis (Figures 1–4) only samples prior to the change in cytome-
ter were included for NK data. The data from the FACSCanto
was included only for the pre/post therapy group (Figure 5).
P<0.001
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FIGURE 1 | Granzyme B in human cytotoxic lymphocytes. Flow
cytometry was used to measure protein expression of granzyme B in
healthy controls. (A) There is an age-dependent increase in CD8 cells
expressing granzyme B. (B) NK expression of granzyme B as measured by
mean channel fluorescence (MCF) does not increase with age. The mean
values are listed for each group, with standard deviation. p Values were
calculated assuming non-parametric analysis. The number of individuals
sampled is shown in parentheses under the age range.
As expected the normal range for the percentages of CD8 cells
expressing Prf and GrB did not change from 2001 to 2011.
SOLUBLE IL 2 RECEPTOR
The plasma concentration of the sIL2R was determined using
the Human sIL2R (sCD25) ELISA Set (BD OptEIA from
BD Biosciences #559104) from 2001 to 2004. From 2004 to
2007, this was changed to a Human sIL2R ELISA Set from
R&D. Since February, 2007, the soluble IL2 receptor has been
determined using the Immulite 1000 platform, a solid-phase,
two-site chemiluminescent immunometric assay system. Solu-
ble sIL2R values were normalized to account for the method
utilized. To establish an age-dependent normal range for
each method, ethylenediaminetetraacetic acid peripheral blood
was obtained from control children of all ages as described
above.
STATISTICAL ANALYSIS
Statistical comparisons between two groups were performed using
the student t -test, assuming two tails and unequal variance as
reported in figure legends.
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FIGURE 2 | Representative histograms of flow cytometry for Prf and GrB in patients with HLH. Dark shading indicates the test antibody. Light gray line is
the isotype control.
RESULTS
GRANZYME B EXPRESSION IN CYTOTOXIC LYMPHOCYTES FROM
HEALTHY CHILDREN
We first established the normal ranges for GrB protein expression
by flow cytometry using residual blood samples collected from
control children of all age groups as previously described. Similar
to the observations by Kogawa et al. (2002) that the percentage of
CD8 cells expressing Prf increases with age in healthy children, we
observed that the percentage of CD 8 cells expressing GrB is very
low in young infants and increases with age to an average 31% in
adults (p< 0.001) (Figure 1A). This is due to the fact that CD8 T
cells in a newborn are naive and therefore have not differentiated
yet into CTL or memory T cells. With antigen exposure in the first
24 months, there is rapid acquisition of CTL and memory cells, to
the same level as adults.
Just as the proportion of Prf-containing NK cells has been
reported to be constant from birth to adulthood in humans
(Kogawa et al., 2002) we found that GrB expression is detectable
in >85% of NK cells at all age groups (not shown). Additionally,
the content of GrB in NK cells is constant, with a MCF of 850
in children 0–6-month-old, 730 in adults, and 783 (99% confi-
dence interval is 783+ 83) with all ages combined (obtained in
our laboratory between 2001 and 2009) (Figure 1B).
GRANZYME B EXPRESSION IN PATIENTS WITH HLH
We analyzed GrB expression in 93 patients who were identified
with known genetic causes of HLH (FHL2, FHL3, FHL5, and
HLHxlp) (Table 1). In order to determine if patients without
clearly established, genetic diagnoses (HLHunk) also exhibited the
same immune signature, we included 37 additional patients who
reported by their physicians as having HLH, of which 14 had EBV-
associated HLH (see Table 1). All patients were referred with a
clinical diagnosis of HLH by their primary physician and had flow
cytometric evaluation of Prf and GrB performed by the DIL.
Typical histograms of Prf and GrB expression in cytotoxic cells
are shown in Figure 2 and the results from all patients with HLH
summarized in Figure 3. Consistent with our hypothesis, we noted
an increased percentage of GrB positive CD8 cells in patients with
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FIGURE 3 | Expression of Prf and GrB in NK and CD8+ lymphocytes in
various subtypes of HLH. CD8+ cells: shown are the percentages of Prf and
GrB positive CD8 cells. GrB and Prf expression was statistically different than
controls in all groups except FHL5. For CD8 data, the p Values are compared
to healthy pediatric controls aged 1–20 years (n=49 for Prf, n=76 for GrB).
NK cells: to evaluate the protein content we analyzed the intensity of the
fluorescent signal per cell, i.e., MCF. The MCF of GrB was increased in
patients with all subtypes of HLH. MCF of Prf was elevated only in patients in
HLHxlp, HLHunk and FHL3 groups. For the NK data, pediatric and adult
controls were used as there is no age dependence (n=116 for Prf, n=97 for
GrB). The error bars represent the standard deviation from the mean. All p
values assume two tails, non-parametric data.
HLH, in all genetic subtypes. This reached statistical significance
for all groups except FHL5, as compared to age-matched healthy
normal controls. The lack of statistical significance in FHL5 is due
to the lower number of children in this group (n= 10), as the
mean level was elevated to the same degree as other groups with
HLH that did reach a p value< 0.01. Prf expression was low (as
expected in FHL2 due to biallelic PRF1 mutations),and statistically
elevated in all other groups except FHL5. We compared all groups
with HLH to controls aged 1–20 years, as the patients with FHL5
were 1 year and older. For the other groups with younger children,
we performed an independent analysis including children aged
0–20 years, but this did not change the statistical significance.
We analyzed the MCF of prf and grB in NK cells as a mea-
sure of protein content per cell to determine if NK cells similarly
upregulated granule proteins. Indeed, GrB content was elevated
in NK cells in patients with HLH regardless of genetic subtype.
The mean GrB signal (MCF) in NK cells was threefold elevated
in all subtypes of HLH, including boys with HLH due to XLP.
Therefore, the immunologic phenotype was not dependent upon
a granule protein pathway defect per se, but instead reflected the
common final pathway for immune activation of CTL and NK.
Interestingly, the Prf was minimally elevated in some, but not all
patients with HLH. It was low, as expected in patients with FHL2
(PRF1 mutations). As the GrB expression was more consistently
(and dramatically) elevated than Prf, we focused on this granule
protein as a marker for immune activation.
GRANZYME B EXPRESSION CORRELATES WITH IMMUNE ACTIVATION
IN HLH
Although the data demonstrate that elevated GrB content in NK
and an increased percentage of GrB expressing CTLs are present
in children with HLH, the correlation of increased GrB detection
for immune activation was unclear. To address this, we reviewed
data from boys diagnosed with XLP but no evidence of HLH at
the time of evaluation. These patients were diagnosed with XLP
after a sibling’s diagnosis or after multiple malignancies. As shown
in Figure 4, patients with XLP without HLH exhibited subtle
increases in GrB detection; whilst the group with HLH had sig-
nals that were three times higher than the control group. This data
suggests that not only is GrB a signature for immune activation in
HLH, but it also increases subtly in individuals with XLP whose
baseline immune activation has not yet reached a critical threshold
for development of HLH.
We also evaluated whether GrB content decreased with
immunosuppression as a second confirmation that protein levels
correlated with immune activation. Therefore, we analyzed data
from 10 patients who had been treated for HLH at our institu-
tion and had at least two samples sent for GrB and Prf testing,
along with concomitant sIL2R measurements. All 10 patients had
Prf/GrB testing at diagnosis and at a second time point, i.e., during
treatment for HLH therapy and prior to bone marrow transplan-
tation. As shown in Table 2, all patients exhibited a decrease in
the gold standard for immune activation, sIL2R, during therapy,
as expected. The GrB expression in CD8+ cells decreased to nor-
mal in 8/10 patients; however, in P8 and P10, GrB expression in
CTL remained markedly elevated despite normalization of other
markers. Likewise, expression of GrB in NK cells decreased in all
but one patient (P1), whose sIL2R remained persistently elevated.
Thus, elevations of GrB may serve as a biomarker of immune
activation in patients with HLH. Interestingly, although the NK
GrB levels dropped, they did not typically normalize, despite a
normalized sIL2R. This is reminiscent of the subtle increases in
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FIGURE 4 | Granzyme B and perforin expression in cytotoxic
lymphocytes from patients with XLP presenting with or without HLH.
Error bars represent standard deviation from the mean. *p<0.001
compared to no HLH and controls, **p<0.05 compared to controls.
GrB seen in boys with XLP but no evidence of HLH. This sug-
gests that NK expression of GrB may be a more sensitive marker
of persistent, dysregulated cytotoxic lymphocyte activation.
DISCUSSION
Our data in patients with HLH shows for the first time that
increased detection of GrB in both CTL and NK are a signature of
HLH-associated immune activation, irrespective of genetic etiol-
ogy. Although expressed constitutively in all human NK cells, GrB
protein levels (as measured by flow cytometry) in human NK cells
were elevated in patients with HLH and decreased with treatment.
This suggests that elevated GrB levels in NK cells may also be a
biomarker of disease activity. As a result of this finding, our physi-
cians now consider elevated NK and/or CTL GrB expression as a
marker of disease activity, providing additional evidence for evi-
dence of immune activation in the cytotoxic compartment. This is
feasible as the diagnostic lab calibrates flow cytometers daily to a
fluorescent standard (beads) and defines age-matched ranges prior
to testing clinical samples. We also noted increased Prf expressing
CD8. In FHL2, due to PRF1 mutations, the Prf levels are generally
absent or severely reduced (Figure 3), but in other forms of HLH,
PRF levels were also increased in NK cells (FHL3, HLHxlp, and
HLHunk).
Occasional samples submitted from patients with HLH exhib-
ited normal levels of GrB expression in cytotoxic lymphocytes. As
blood is sent from outside physicians for testing without infor-
mation regarding treatment, it is likely that these patients had
already started immunosuppressive therapy, but this could not be
confirmed. Additionally, newborns are occasionally tested prior
to the onset of HLH symptomatology if an older sibling has died
from HLH. The inclusion of patients with clinically silent disease
in our analysis of 130 patients may have led to an underestima-
tion of the maximum GrB expression possible in all subtypes
of HLH.
Based on the current understanding of the pathophysiology
of HLH, we would predict to find increased Prf/GrB expression
in CD8 cells in patients with HLH. The murine model has clearly
shown activation of this T cell compartment and CD8 cells acquire
both granzymes and Prf during activation and differentiation. As
CTL differentiation is dependent upon T cell receptor stimula-
tion, our data implies that antigen presentation via MHC class I is
a primary determinant of the immune activation. Viral triggers are
presumed in HLH, although not always identified in young infants
presenting with HLH. In contrast to CTL activation, elevated NK
levels of Prf and GrB have not previously been described under
pathologic conditions. Our pre/post evaluation of patients with
HLH and the data for individuals with XLP suggests the elevation
in these protein markers are a result of immune activation and/or
dysregulation.
The finding of NK activation in patients with HLH due to
BIRC4 mutations is interesting in that no clear secretory granule
defect has been identified in these patients. It is consistent with
the fact that HLH is often a presenting symptom in these patients.
(Marsh et al., 2010) Therefore, elevated GrB levels may not simply
reflect a failure of secretion or degranulation of this granule associ-
ated protein. If this were true, we would expect the highest values to
be found in cytotoxic lymphocytes with an inability to degranulate
(Munc 13-4 and STXBP2 deficiency). There was no clear differ-
ence between sub-groups of HLH. We have not yet addressed the
mechanism for increased Prf/GrB detection in NK, but possibili-
ties include increased transcription, post-translational regulation
of mRNA stability, increased secretory granule production, and/or
increased half-life of the proteins.
Regulation of GrB in NK has been described at the level of
mRNA transcription and post-translational regulation through
microRNAs, largely through in vitro studies of cytokine activation
(Kim et al., 2011; Trotta et al., 2011; Wang et al., 2012). As ele-
vated pro-inflammatory cytokines have been described in HLH, it
is possible that blood and tissue-derived cytokines drive NK and
CTL activation of GrB. It is also likely that ongoing antigenic stim-
ulation (due to a failure to eliminate antigen presenting or virally
infected cells) provides an ongoing activating stimulus to NK and
CTL. Further studies in murine models of HLH will help clarify
these remaining questions.
Although ours is the first study to report GrB protein expres-
sion in CTL and NK cells in patients with immune activation due
to HLH, GrB transcripts in the blood and GrB ELISPOT measure-
ments of PBMC have been proposed as a biomarker of immune
activation to screen for CTL activation leading to graft rejection
following solid organ transplants (Altimari et al., 2008; Truong
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FIGURE 5 | Granzyme B protein content in cytotoxic
lymphocytes is a marker of HLH disease activity. Ten patients
had a follow-up test performed after initiating treatment for HLH (for
description of patients seeTable 2). Shown are the first and second
data points for each patient. Two patients had persistent immune
activation, as measured by the gold standard, sIL2R. These two
patients also had persistent GrB elevation in the NK compartment
(Table 2).
et al., 2008). For example, in patients who received intestinal trans-
plantation, blood monitoring of GrB and Prf RNA were diagnostic
markers of acute graft rejection, increasing prior to histological
diagnosis of a rejection, and then returning back to baseline with
initiation of therapy (Altimari et al., 2008). In addition to inves-
tigations following solid organ transplants, studies have evaluated
whether GrB levels are elevated in patients with active viral infec-
tions such as children with Respiratory Syncytial Virus infection
and patients infected with EBV or HIV (Spaeny-Dekking et al.,
1998; Bem et al., 2008). Finally, GrB levels in the blood have been
associated with disease activity in patients with rheumatoid arthri-
tis (Goldbach-Mansky et al., 2005). No direct comparison have
been made of flow cytometry measurements to ELISA or RNA
measurements of GrB, making comparisons with these studies
challenging to interpret. Evaluation of NK/CTL GrB detection in
patients with macrophage activation syndrome (MAS) in patients
with juvenile idiopathic arthritis at our center revealed variable
results, with increased detection in some, but not all patients
with active disease (Grom et al., 2003) and data not shown),
highlighting the subtle differences between HLH and MAS.
In summary, we have shown that elevated GrB expression in NK
and CTL is a signature of immune activation in patients with HLH
regardless of the genetic background. GrB staining of cytotoxic
lymphocytes is included routinely as an internal control in the
diagnostic immunology lab at our center in the assessment of Prf
protein. Our data suggest that it may serve as a useful biomarker of
disease activity. As a retrospective study limited to a large cohort
of patients with HLH, we have not addressed the specificity of our
findings to HLH. Future studies are needed to determine the utility
of our findings in other inflammatory conditions such as critically
ill patients with systemic inflammatory response syndrome, graft
versus host disease, or autoimmune diseases. We would predict
that any disorder with profound CTL/NK immune activation sec-
ondary to systemic viral activation may share a similar immune
profile. Characterization of cytotoxic lymphocyte activation by
assessment of GrB detection may thus be a useful tool clinically
and in research settings.
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